Previous Pause Next
Home >> Resource Center >> Publication >>
Book
Biotech 2010 Life Sciences: Adapting for Success PDF Print E-mail
Saturday, 27 March 2010 06:20

http://www.ebionews.com/images/stories/07_Features/19_The_Burrill_Report/2010-03/burril%20book.jpgCharles Darwin told us that it is not the strongest of the species that survives, nor the most intelligent, but the one most responsive to change. Biotech 2010—Life Sciences: Adapting for Success, Burrill & Company’s latest annual report on the industry, provides insight into biotech’s changing environment and how not to just survive but succeed.

Learn how to thrive

Available in March 2010, the publication provides thoughtful information and analysis on how companies need to adapt to major challenges to their business development in order to be successful in 2010 and beyond. These include: raising capital, impending healthcare reform, comparative effectiveness research, generics, biosimilars, reimbursement pressures and regulatory changes.
 
 
In addition Biotech 2010 presents:

• Comprehensive 2009 industry financials, private and public capital raised, M&A/Partnering activity of life sciences companies operating in the United States, Europe, Canada, and Asia.
 
• Analysis on key developments in healthcare, personalized medicine, biogreentech, emerging technologies, politics and policy and globalization…and much more.
 

Click here to view the Table of Contents.

Order now:

Print : $300.00

Electronic Version: $275.00

Print and Electronic Bundle: $495.00

 
JUST PUBLISHED: Biotech 2009 - Life Sciences: Navigating the Sea Change PDF Print E-mail
Monday, 30 March 2009 09:39

Biotech 2009-Life Sciences: Navigating the Sea

Change is the 23rd edition of this yearly publication. It provides a compass to guide you through the current financial market turmoil. The 400-plus page book contains analysis and perspectives on the performance of the industry in 2008 and projections for 2009 and beyond.

The biotech industry has had nearly 40 years of easy access to inexpensive capital. The capital markets have permanently restructured, making access to capital more difficult and expensive to access. The changes mean:

  • Buy-side interest and resources are reduced.
  • Venture capitalist and private investors no longer can rely on IPOs for exits.
  • Big Pharma is not as eager to make deals. As these companies see it, technology will be cheaper to buy if they wait.
  • Falling oil prices may slow the momentum for alternate fuels.
Read more...